Cancer

CORRECTING AND REPLACING: Ludwig Enterprises Inc. Announces AI-Powered Cancer Screening Technology

This press release replaces the release issued today at 9:15am EDT.Revolutionary AI-driven cheek swab test poised to transform early cancer…

1 year ago

Sona Nanotech Closes Private Placement Financing to Raise $1,643,750 in Gross Proceeds

Halifax, Nova Scotia--(Newsfile Corp. - September 24, 2024) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona")…

1 year ago

Sona Nanotech Closes Private Placement Financing to Raise $1,643,750 in Gross Proceeds

Halifax, Nova Scotia--(Newsfile Corp. - September 24, 2024) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona")…

1 year ago

Tigerlily Foundation’s Annual Empower Ball: An Evening of Recognizing Impact in Health Equity, Empowerment and Transformation

WASHINGTON, DC / ACCESSWIRE / September 24, 2024 / Tigerlily Foundation proudly announces its Annual EmPOWER Ball, an evening dedicated…

1 year ago

Curium Announces the Official Opening its New Netherlands Facility for the Production of Lutetium-177 – a Game Changer Therapy Isotope for Cancer Patients Worldwide

Curium Opens New Lu-177 Production Facility, Transforming Cancer Treatment Curium project team with Kate Briant, Ciril Faia, Frank de Lange…

1 year ago

Altamira Therapeutics Provides Business Update and First Half 2024 Financial Results

Hamilton, Bermuda, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Company to host conference call today at 8.30 a.m. ETContinued progress within…

1 year ago

Starton Therapeutics’ Chief Executive Officer Chosen as 2024 Honoree by the Icla da Silva Foundation

PARAMUS, N.J., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc. (“Starton” or the “Company”), a clinical-stage biotechnology company transforming…

1 year ago

Barinthus Bio Initiates Phase 1 Clinical Trial of VTP-1000 for the Treatment of Celiac Disease

Investigational immunotherapy candidate, VTP-1000, seeks to address significant unmet need in people with celiac disease.An estimated one in 100 people…

1 year ago

First Patient Enrolled in Phase I Program in STK11 Mutant Non-Small Cell Lung Cancer at Moffitt Cancer Center

MINNEAPOLIS, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage company developing disruptive therapeutics for the…

1 year ago

Immutep Receives A$3.6 million R&D Tax Incentive from French Government

Media Release SYDNEY, AUSTRALIA, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company”),…

1 year ago